141 related articles for article (PubMed ID: 31965301)
1. Can portal hypertension and hepatic decompensation be predicted?
Kaji K; Yoshiji H
J Gastroenterol; 2020 Jun; 55(6):662-663. PubMed ID: 31965301
[No Abstract] [Full Text] [Related]
2. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
[TBL] [Abstract][Full Text] [Related]
4. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
5. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension.
Lisotti A; Azzaroli F; Cucchetti A; Buonfiglioli F; Cecinato P; Calvanese C; Simoni P; Arena R; Montagnani M; Golfieri R; Colecchia A; Festi D; Mazzella G
Liver Int; 2016 Sep; 36(9):1313-21. PubMed ID: 26786880
[TBL] [Abstract][Full Text] [Related]
6. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
[TBL] [Abstract][Full Text] [Related]
7. Hepatic-associated immunoglobulin-A nephropathy in a child with liver cirrhosis and portal hypertension.
Alghamdi SA; Saadah OI; Almatury N; Al-Maghrabi J
Saudi J Gastroenterol; 2012; 18(3):214-6. PubMed ID: 22626802
[TBL] [Abstract][Full Text] [Related]
8. von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.
Kalambokis GN; Baltayiannis G; Christodoulou D
World J Gastroenterol; 2016 May; 22(19):4786-8. PubMed ID: 27217711
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostic aspects of hepatochirrhosis and portal hypertension syndrome].
Simonov VV
Vestn Khir Im I I Grek; 1979 Jul; 123(7):132-5. PubMed ID: 505828
[No Abstract] [Full Text] [Related]
10. [Radionuclide and ultrasound studies in liver cirrhosis with portal hypertension].
Khodzhibekov MKh; Rikhsieva LE; Nazyrov FG
Med Radiol (Mosk); 1988 Aug; 33(8):42-7. PubMed ID: 3045472
[TBL] [Abstract][Full Text] [Related]
11. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
Ripoll C; Groszmann R; Garcia-Tsao G; Grace N; Burroughs A; Planas R; Escorsell A; Garcia-Pagan JC; Makuch R; Patch D; Matloff DS; Bosch J;
Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
[TBL] [Abstract][Full Text] [Related]
12. [Neuropsychic disorders in liver cirrhosis with portal hypertension].
Bogachenko VP
Zh Nevropatol Psikhiatr Im S S Korsakova; 1971; 71(7):1079-83. PubMed ID: 5135154
[No Abstract] [Full Text] [Related]
13. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
[TBL] [Abstract][Full Text] [Related]
14. [Mathematical algorithm for the determination of admissible volume of surgical intervention for portal hypertension in patients with liver cirrhosis].
Rusyn VI; Peresta IuIu; Chavarha MI
Klin Khir; 2002 Jul; (7):11-3. PubMed ID: 12378903
[TBL] [Abstract][Full Text] [Related]
15. The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study.
Nguyen GC; Correia AJ; Thuluvath PJ
Dis Colon Rectum; 2009 Aug; 52(8):1367-74. PubMed ID: 19617746
[TBL] [Abstract][Full Text] [Related]
16. [The treatment in ulcerative hemorrhages in patients with liver cirrhosis and portal hypertension].
Khanevich MD; Koshevoĭ AP
Vestn Khir Im I I Grek; 2000; 159(2):27-30. PubMed ID: 10890064
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and treatment of esophageal varices in the cirrhotic patient.
Ashkenazi E; Kovalev Y; Zuckerman E
Isr Med Assoc J; 2013 Feb; 15(2):109-15. PubMed ID: 23516775
[TBL] [Abstract][Full Text] [Related]
18. [Hemodynamic and functional aspects of portal hypertension decompensation in liver cirrhosis].
Kalita NIa; Kotenko OG; Bulanov KI; Furmanenko ED; Egorova OE
Klin Khir (1962); 1994; (11):37-41. PubMed ID: 7658658
[TBL] [Abstract][Full Text] [Related]
19. Comparison between ultrasonographic signs and the degree of portal hypertension in patients with cirrhosis.
Vilgrain V; Lebrec D; Menu Y; Scherrer A; Nahum H
Gastrointest Radiol; 1990; 15(3):218-22. PubMed ID: 2187730
[TBL] [Abstract][Full Text] [Related]
20. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.
Garcia-Tsao G; Abraldes JG; Berzigotti A; Bosch J
Hepatology; 2017 Jan; 65(1):310-335. PubMed ID: 27786365
[No Abstract] [Full Text] [Related]
[Next] [New Search]
